Lung Cancer News

Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC

Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC

Researchers enrolled 222 patients with completely resected stage II-IIIA (N1-N2) NSCLC to receive adjuvant gefitinib or cisplatin plus vinorelbine.

NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms

NSCLC: Tissue, Rather Than Liquid, Biopsy Recommended for Identifying Resistance Mechanisms

Researchers evaluated the biopsies and outcomes of 5 patients with an EGFR-activating mutation who were initially treated with a first- or second-generation EGFR-TKI.

Bevacizumab Not Recommended as Adjuvant Therapy in NSCLC

Bevacizumab Not Recommended as Adjuvant Therapy in NSCLC

Investigators randomly assigned 1501 patients with completely resected stage IB to IIIA NSCLC to receive chemotherapy alone or chemotherapy plus bevacizumab.

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

Liquid Biopsies: An Emerging, Effective, Versatile Monitoring Modality in Lung Cancer

In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.

First-line Osimertinib for EGFR-mutation Positive NSCLC

First-line Osimertinib for EGFR-mutation Positive NSCLC

The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.

FDA Approves Alectinib as First-line Therapy for ALK-positive NSCLC

FDA Approves Alectinib as First-line Therapy for ALK-positive NSCLC

Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Anticoagulant Therapy Does Not Improve Overall Survival in Small-cell Lung Cancer

Anticoagulant Therapy Does Not Improve Overall Survival in Small-cell Lung Cancer

Previous study showed that anti-coagulants may not only have anti-tumorigenic activity, but also the potential to provide significant survival benefit for patients with SCLC.

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC

For the phase 3 KEYNOTE-024 study, researchers randomly assigned 305 patients with advanced NSCLC of any histological type to 35 cycles of pembrolizumab or 4 to 6 cycles of investigator's choice chemotherapy.

Lung Cancer Treatment in North America: Recent Advances and Future Promises

Lung Cancer Treatment in North America: Recent Advances and Future Promises

At the closing plenary session of WCLC, Paul A. Bunn, Jr, MD, presented a treatment algorithm for lung cancer and discussed where lung cancer research in North America is heading.

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC

A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation

Exon 20 mutations account for 4% to 10% of EGFR mutations in NSCLC and are refractory to EGFR TKIs; there are no targeted therapies available for this patient population.

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC

For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC

ctDNA next generation sequencing of patient blood samples detected oncogenic drivers in 27 (36%) patients, including HER2 exon 20 insYVMA, BRAF L597Q, and MET exon14 mutations.

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

Durvalumab Does Not Worsen Quality of Life Among Patients With Unresectable NSCLC

During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC trial.

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC

Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin.

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC

For this cross-sectional study, researchers collected the data of 1030 adult patients with advanced NSCLC from medical chart reviews and various patient questionnaires.

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC

One-hundred and eight patients received cisplatin plus docetaxel in the control arm; 392 patients in the experimental arm received varying treatments according to BRCA1 mRNA expression levels.

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival

Researchers evaluated survival and socioeconomic data from 1,150,722 patients with NSCLC to determine particular factors that may predict OS.

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC

Researchers administered savolitinib 600 mg plus gefitinib 250 mg to 44 patients, of whom 6 were T790M-positive and 5 were T790M-negative.

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer

Investigators randomly assigned 95 patients with ED-SCLC to receive pazopanib 800 mg daily or placebo.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters